Compounds acting as AMP-activated protein kinase (AMPK) activators and prostaglandin G/H synthase 2 (PTGS2; COX2) inhibitors have been reported by Nanjing Shupeng Lifescience to be useful for the treatment of pain and inflammatory disorders, among others.
Shanghai Jemincare Pharmaceuticals Co. Ltd. and Jiangxi Jemincare Group Co. Ltd. have patented compounds reported to be useful for the treatment of fungal infections.
Haisco Pharmaceutical Group Co. Ltd. has described protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Hainan Sparkle Therapeutics Co. Ltd. has disclosed fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.
Reduced expression of nuclear factor erythroid 2-related factor 2 (Nrf2) is observed in humans and animal models of Alzheimer’s disease (AD), with its activation being a promising therapeutic approach.
Gb Sciences Inc. has received promising preclinical results in an interim report from a study using its plant-based compounds in preclinical zebrafish models of stress at the National Research Council of Canada (NRC).
Turn Biotechnologies Inc. has presented interim preclinical data that demonstrates treating T cells with its proprietary technologies can significantly increase their ability to kill cancer.
Amplifica Holdings Group Inc. has closed a US$11.8 million series A preferred stock financing, the funds from which will be used to advance the development of its proprietary compounds for the treatment of androgenic alopecia in males and females.
RSS
